Ontogeny and regulation of the serotonin transporter

Providing insights into human disorders

Lynette C Daws, Georgianna G Gould

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Serotonin (5-hydroxytryptamine, 5-HT) was one of the first neurotransmitters for which a role in development was identified. Pharmacological and gene knockout studies have revealed a critical role for 5-HT in numerous processes, including cell division, neuronal migration, differentiation and synaptogenesis. An excess in brain 5-HT appears to be mechanistically linked to abnormal brain development, which in turn is associated with neurological disorders. Ambient levels of 5-HT are controlled by a vast orchestra of proteins, including a multiplicity of pre- and post-synaptic 5-HT receptors, heteroreceptors, enzymes and transporters. The 5-HT transporter (SERT, 5-HTT) is arguably the most powerful regulator of ambient extracellular 5-HT. SERT is the high-affinity uptake mechanism for 5-HT and exerts tight control over the strength and duration of serotonergic neurotransmission. Perturbation of its expression level or function has been implicated in many diseases, prominent among them are psychiatric disorders. This review synthesizes existing information on the ontogeny of SERT during embryonic and early postnatal development though adolescence, along with factors that influence its expression and function during these critical developmental windows. We integrate this knowledge to emphasize how inappropriate SERT expression or its dysregulation may be linked to the pathophysiology of psychiatric, cardiovascular and gastrointestinal diseases.

Original languageEnglish (US)
Pages (from-to)61-79
Number of pages19
JournalPharmacology and Therapeutics
Volume131
Issue number1
DOIs
StatePublished - Jul 2011

Fingerprint

Serotonin Plasma Membrane Transport Proteins
Serotonin
Psychiatry
Gene Knockout Techniques
Gastrointestinal Diseases
Serotonin Receptors
Brain
Nervous System Diseases
Synaptic Transmission
Cell Division
Neurotransmitter Agents
Cardiovascular Diseases
Pharmacology
Enzymes

Keywords

  • Antidepressants
  • Cardiovascular and gastrointestinal disease
  • Gene variants
  • Ontogeny
  • Psychiatric disease
  • Serotonin transporter

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Ontogeny and regulation of the serotonin transporter : Providing insights into human disorders. / Daws, Lynette C; Gould, Georgianna G.

In: Pharmacology and Therapeutics, Vol. 131, No. 1, 07.2011, p. 61-79.

Research output: Contribution to journalArticle

@article{ca9ddaeeed064e14910de3860ad0cb56,
title = "Ontogeny and regulation of the serotonin transporter: Providing insights into human disorders",
abstract = "Serotonin (5-hydroxytryptamine, 5-HT) was one of the first neurotransmitters for which a role in development was identified. Pharmacological and gene knockout studies have revealed a critical role for 5-HT in numerous processes, including cell division, neuronal migration, differentiation and synaptogenesis. An excess in brain 5-HT appears to be mechanistically linked to abnormal brain development, which in turn is associated with neurological disorders. Ambient levels of 5-HT are controlled by a vast orchestra of proteins, including a multiplicity of pre- and post-synaptic 5-HT receptors, heteroreceptors, enzymes and transporters. The 5-HT transporter (SERT, 5-HTT) is arguably the most powerful regulator of ambient extracellular 5-HT. SERT is the high-affinity uptake mechanism for 5-HT and exerts tight control over the strength and duration of serotonergic neurotransmission. Perturbation of its expression level or function has been implicated in many diseases, prominent among them are psychiatric disorders. This review synthesizes existing information on the ontogeny of SERT during embryonic and early postnatal development though adolescence, along with factors that influence its expression and function during these critical developmental windows. We integrate this knowledge to emphasize how inappropriate SERT expression or its dysregulation may be linked to the pathophysiology of psychiatric, cardiovascular and gastrointestinal diseases.",
keywords = "Antidepressants, Cardiovascular and gastrointestinal disease, Gene variants, Ontogeny, Psychiatric disease, Serotonin transporter",
author = "Daws, {Lynette C} and Gould, {Georgianna G}",
year = "2011",
month = "7",
doi = "10.1016/j.pharmthera.2011.03.013",
language = "English (US)",
volume = "131",
pages = "61--79",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Ontogeny and regulation of the serotonin transporter

T2 - Providing insights into human disorders

AU - Daws, Lynette C

AU - Gould, Georgianna G

PY - 2011/7

Y1 - 2011/7

N2 - Serotonin (5-hydroxytryptamine, 5-HT) was one of the first neurotransmitters for which a role in development was identified. Pharmacological and gene knockout studies have revealed a critical role for 5-HT in numerous processes, including cell division, neuronal migration, differentiation and synaptogenesis. An excess in brain 5-HT appears to be mechanistically linked to abnormal brain development, which in turn is associated with neurological disorders. Ambient levels of 5-HT are controlled by a vast orchestra of proteins, including a multiplicity of pre- and post-synaptic 5-HT receptors, heteroreceptors, enzymes and transporters. The 5-HT transporter (SERT, 5-HTT) is arguably the most powerful regulator of ambient extracellular 5-HT. SERT is the high-affinity uptake mechanism for 5-HT and exerts tight control over the strength and duration of serotonergic neurotransmission. Perturbation of its expression level or function has been implicated in many diseases, prominent among them are psychiatric disorders. This review synthesizes existing information on the ontogeny of SERT during embryonic and early postnatal development though adolescence, along with factors that influence its expression and function during these critical developmental windows. We integrate this knowledge to emphasize how inappropriate SERT expression or its dysregulation may be linked to the pathophysiology of psychiatric, cardiovascular and gastrointestinal diseases.

AB - Serotonin (5-hydroxytryptamine, 5-HT) was one of the first neurotransmitters for which a role in development was identified. Pharmacological and gene knockout studies have revealed a critical role for 5-HT in numerous processes, including cell division, neuronal migration, differentiation and synaptogenesis. An excess in brain 5-HT appears to be mechanistically linked to abnormal brain development, which in turn is associated with neurological disorders. Ambient levels of 5-HT are controlled by a vast orchestra of proteins, including a multiplicity of pre- and post-synaptic 5-HT receptors, heteroreceptors, enzymes and transporters. The 5-HT transporter (SERT, 5-HTT) is arguably the most powerful regulator of ambient extracellular 5-HT. SERT is the high-affinity uptake mechanism for 5-HT and exerts tight control over the strength and duration of serotonergic neurotransmission. Perturbation of its expression level or function has been implicated in many diseases, prominent among them are psychiatric disorders. This review synthesizes existing information on the ontogeny of SERT during embryonic and early postnatal development though adolescence, along with factors that influence its expression and function during these critical developmental windows. We integrate this knowledge to emphasize how inappropriate SERT expression or its dysregulation may be linked to the pathophysiology of psychiatric, cardiovascular and gastrointestinal diseases.

KW - Antidepressants

KW - Cardiovascular and gastrointestinal disease

KW - Gene variants

KW - Ontogeny

KW - Psychiatric disease

KW - Serotonin transporter

UR - http://www.scopus.com/inward/record.url?scp=79956198390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956198390&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2011.03.013

DO - 10.1016/j.pharmthera.2011.03.013

M3 - Article

VL - 131

SP - 61

EP - 79

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 1

ER -